Sahirzeeshan (Sahir) Ali

Lila Sciences is the world’s first scientific superintelligence platform and autonomous lab for life, chemistry, and materials science. We are building the foundation to apply AI to every aspect of the scientific method, enabling scientists to bring forth solutions in human health and sustainability at a pace and scale never experienced before.

Inference is the engine that powers AI, and Groq was built from the silicon up to deliver the worlds fastest inference at scale. We pioneered the LPU—the first processor designed specifically for AI inference—and are transforming that innovation into a global cloud platform powering production AI workloads. With the capital, infrastructure, and team to execute, were uniquely positioned to define the next era of AI infrastructure. The opportunity is massive, and its still wide open. Now lets go build it!

Atomic AI is a well-funded, early-stage biotech company transforming the rational design of molecules and medicines through the cutting-edge fusion of artificial intelligence and structural biology. Atomic’s unique R&D platform, based on research featured on the cover of Science (doi.org/10.1126/science.abe5650), provides new strategies to treat or cure previously-undruggable diseases by targeting RNA structure. We are an interdisciplinary team working across computational and experimental biology and believe that our strongest asset is our people. Were hiring! https://boards.greenhouse.io/atomai

Ashvattha Therapeutics is developing a new class of drugs that identify and treat diseased cells with unprecedented precision. Our proprietary hydroxyl dendrimer (HD) platform, exclusively licensed from Johns Hopkins University, allows for the creation of hydroxyl dendrimer therapeutics (HDTs), which link known small molecule drugs to HDs for selective delivery with sustained effect in diseased tissues. We believe this approach to precision medicine has the potential to change the standard of care across neurology, ophthalmology, hyperinflammatory diseases and neuro-oncology.

Lila Sciences is the world’s first scientific superintelligence platform and autonomous lab for life, chemistry, and materials science. We are building the foundation to apply AI to every aspect of the scientific method, enabling scientists to bring forth solutions in human health and sustainability at a pace and scale never experienced before.

Inference is the engine that powers AI, and Groq was built from the silicon up to deliver the worlds fastest inference at scale. We pioneered the LPU—the first processor designed specifically for AI inference—and are transforming that innovation into a global cloud platform powering production AI workloads. With the capital, infrastructure, and team to execute, were uniquely positioned to define the next era of AI infrastructure. The opportunity is massive, and its still wide open. Now lets go build it!

Flagship Pioneering is a biotechnology company that invents and builds platform companies, each with the potential for multiple transformative human health and sustainability products. Since its launch in 2000, Flagship has originated and fostered more than 100 scientific ventures. The current Flagship ecosystem comprises over 40 companies, including Denali Therapeutics, Foghorn Therapeutics, Generate:Biomedicines, Inari, Indigo Agriculture, and Tessera Therapeutics.

Atomic AI is a well-funded, early-stage biotech company transforming the rational design of molecules and medicines through the cutting-edge fusion of artificial intelligence and structural biology. Atomic’s unique R&D platform, based on research featured on the cover of Science (doi.org/10.1126/science.abe5650), provides new strategies to treat or cure previously-undruggable diseases by targeting RNA structure. We are an interdisciplinary team working across computational and experimental biology and believe that our strongest asset is our people. Were hiring! https://boards.greenhouse.io/atomai

Ashvattha Therapeutics is developing a new class of drugs that identify and treat diseased cells with unprecedented precision. Our proprietary hydroxyl dendrimer (HD) platform, exclusively licensed from Johns Hopkins University, allows for the creation of hydroxyl dendrimer therapeutics (HDTs), which link known small molecule drugs to HDs for selective delivery with sustained effect in diseased tissues. We believe this approach to precision medicine has the potential to change the standard of care across neurology, ophthalmology, hyperinflammatory diseases and neuro-oncology.